QuiremSpheres® is an innovative way of treating advanced unresectable cancers in the liver by means of radioembolization. It is the only commercially available radioembolization product based on holmium-166. Holmium has unique imaging properties, allowing the physician to treat what he sees and see what he treats.
Radioembolization is a cancer treatment in which radioactive particles are delivered to a tumor through the bloodstream. The particles lodge in the tumor and emit radiation that kills cancer cells. Radioembolization is most often used on cancers in the liver.
LEARN MORE ABOUT RADIOEMBOLIZATION
QuiremSpheres® can be visualized with SPECT and MR imaging. By means of our proprietary software tool Q-Suite™, SPECT and MR images of QuiremSpheres® can be converted into 3D dose distributions, enabling clincians to quantitatively determine the dose received by the targeted tumors and healthy liver tissue.
The first and only commercial radioembolization solution based on holmium-166
Based on more than 15 years of technological advancement and clinical research
Quantitative SPECT and MR imaging properties enable dosimetric treatment verication
QuiremSpheres® is not available for sale in all countries. This information is provided only in respect to markets where QuiremSpheres® is approved or cleared. QuiremSpheres® is not FDA cleared in the US for sale.
Q-Suite™ is not yet commercially available in any country and has no CE mark. Please contact your Terumo local sales representative for more information. Q-Suite™ is not FDA cleared in the US for sale.